Thomas Sciascia, Chief Scientific Officer at Trevi Therapeutics, Inc. (TRVI), sold 50,165 shares at $2.76 ($139K) on 2024-08-16, disclosed to the SEC on 2024-08-16.
Open-market sale of $139k TRVI by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.75 | 100 | $275 | 0.2% |
| 2 | $2.79 | 12,745 | $36K | 25.6% |
| 3 | $2.76 | 18,660 | $52K | 37.1% |
| 4 | $2.76 | 18,660 | $52K | 37.1% |
| Total | $2.77 avg | 50,165 | $139K | 100% |
| Filing → |
| TRVI | SELL | 2024-05-31 | $272K | — | Filing → |